European Union: European Commission Sets Its Sights On Allegedly Excessive Drug Prices

Last Updated: June 21 2017
Article by Christian Fulda and Philipp Werner

In Short

The Background: Following its 2008 pharmaceutical sector inquiry, the European Commission has largely followed through on its commitment to intensify competition law enforcement in this industry, although it has focused mainly on pay-for-delay agreements.

The Action: On May 15, 2017, the Commission announced the opening of a formal investigation into concerns that Aspen Pharma has engaged in excessive pricing with regards to several cancer drugs.

Looking Ahead: The action could signal a paradigm shift in the Commission's stated enforcement priorities in the sector and risks generating considerable uncertainty as to the legality of individual pricing practices of pharmaceutical companies.


In the European Union, Big Pharma has been operating with a target on its back for the best part of the last decade. Following its 2008 sector inquiry into the pharmaceutical sector, the Commission vowed to clamp down on firms engaging in anticompetitive practices. In particular, certain defensive patenting strategies, refusals to grant licenses on unused patents, as well as pay-for-delay agreements had been earmarked as being ripe for competition law enforcement. Eight years after the conclusion of the sector enquiry, it is clear that the Commission has largely been true to its stated priorities. Against this backdrop, the announcement of an investigation into excessive prices in the pharmaceutical sector marks a significant departure from past practice with potentially far-reaching consequences.

Competition Law Enforcement of Excessive Prices Called into Question

Exploitative practice par excellence, excessive pricing would appear to be a prime target for competition watchdogs. And yet, despite their deleterious effects on consumer welfare and the black letter of Art. 102(a) TFEU, direct control of high prices through competition law enforcement raises numerous issues. Indeed, it has been widely suggested that high prices should be condemned only where they generate exclusionary effects. The reasons for such caution are numerous. In particular, many have argued that in markets characterized by low barriers to entry, the extraction of monopoly rents by a dominant firm could be self-defeating in that it attracts new entrants to the market.

Under another particularly relevant argument for present purposes, regulatory intervention is viewed as counterproductive because monopoly profits are needed to carry out expensive research and development. As such, competition enforcement, it is said, would have a chilling effect on investments and innovation. Most convincing perhaps is the suggestion that crafting an administrable legal test, which would enable competition authorities to determine whether prices are indeed "excessive" (and, conversely, what constitutes a reasonable price with an acceptable profit margin), is fraught with difficulties. Moreover, assuming such a test could be articulated, regulators would then be faced with the equally difficult task of designing an effective and adequate remedy.

These challenges no doubt explain why excessive pricing as a basis for regulatory intervention seldom has been used.

New-Found Appetite to Challenge Drug Price-Gougers

Price-gouging in the pharmaceutical industry has garnered widespread media attention and has become both highly topical and politicized in many jurisdictions. In Europe, several national competition authorities have been at the forefront of this issue. In particular, the UK Competition and Markets Authority ("CMA") has been among the most aggressive, as evidenced by its two December 2016 decisions, respectively: (i) fining Pfizer and its distributor Flynn Pharma £89.6 million for alleged abuse of a dominant position by increasing prices of the anti-epilepsy drug phenytoin sodium by up to 2,600 percent following its debranding in September 2012; and (ii) issuing a statement of objections against Actavis for alleged abuse of a dominance position in connection with its price increases of up to 12,000 percent in relation to debranded hydrocortisone tablets. Moreover, the CMA is currently investigating Canadian producer Concordia International for the high prices it has charged to supply certain pharmaceutical products.

Besides in the United Kingdom, authorities in Italy and Spain have also sought to rein in price-gouging by pharmaceutical firms. On October 14, 2016, the Italian competition authority (AGCM) fined Aspen more than €5 million for increasing prices of four of its anticancer drugs by up to 1,500 percent. Acting on a tipoff from its Italian counterpart, the Spanish competition authority (CNMC) has recently followed suit by announcing on February 3, 2017, an investigation into whether Aspen and its Spanish distributor Deco Pharma have applied excessively high prices in relation to several of the former's anticancer drugs.

EU Aspen Probe

On May 15, 2017, the Commission announced the opening of a formal investigation into Aspen's pricing practices in relation to five of its anticancer drugs. The probe, which the Commission has indicated will be treated "as a matter of priority," will cover the entire European Economic Area, with the exception of Italy, where Aspen already has been condemned.

In order to establish the alleged infringement, the Commission will first have to prove Aspen's dominance on the market despite the fact that the patents on the contentious drugs have long since expired. Assuming dominance is found, the Commission will then have to pinpoint the level at which prices became excessive. This latter endeavor will undoubtedly prove to be highly contentious, given the problems associated with the legal test for establishing excessive pricing under EU competition law.

Indeed, the approach, which dates back to a seminal case of the early 1970s, looks at whether prices bear "no reasonable relation to the economic value of the product." To this end, the Commission must first determine whether the difference between the cost incurred and the prices actually charged are excessive. However, cost-price analyses are notoriously fraught with difficulties and are often not the only indicator of economic value. This is even more the case in the context of the pharmaceutical industry, where costs related to the high failure rate in bringing drugs to market are often difficult to ascertain.

Nevertheless, assuming the first prong of the test is fulfilled, the Commission will then have to establish that the prices are "unfair," either in themselves or when compared to the prices of competing products. The complexity of establishing the "unfairness" of a given price is well documented. In this regard, the Commission will have to factor in the possibility that high prices of a particular drug may simply reflect its superior therapeutic efficacy, as well as the fact that the pharmaceutical sector is highly regulated.

The Upshot

Much like its other European counterparts, the Commission appears to be setting its sights on pharmaceutical companies engaging in drastic price increases of "niche" off-patent medicines sold only in low volumes due to scarce levels of demand. Although this new trend may indeed prove to be confined, it is nonetheless significant in several respects.

First, the difficulties identified above relating to the use of excessive pricing as a basis for competition law enforcement remain relevant today. As such, pharmaceutical companies will be forced to operate within an increasingly uncertain legal environment. Indeed, not only will they struggle to ascertain whether they can be considered dominant on a given product and geographic market, but they will also be faced with the near impossible task of determining whether their prices are excessive and unfair.

Second, the EU Aspen probe suggest that, at least in the context of the pharmaceutical industry, exploitative practices will no longer play second fiddle to exclusionary behavior. Given the Commission's track record in this sector thus far and the Guidelines on its enforcement priorities in applying Article 102 TFEU, such a development would mark something of a paradigm shift. Finally, although the public outcry generated by certain drug pricing strategies is understandable, there is much to be said about competition law being used as a panacea to remedy the ills of other areas of the law that might be best addressed by other means.


Three Key Takeaways

  1. The Commission's probe into Aspen's allegedly excessive prices suggests that, at least in the context of the pharmaceutical industry, exploitative practices will no longer play second fiddle to exclusionary behavior.
  2. Although this new trend may prove to be confined to drastic price increases of niche off-patented drugs supplied in low volumes, it is nonetheless conducive to significant legal uncertainty.
  3. The probe may also signal a willingness to use competition law as a panacea to remedy the ills of other areas of the law.

Amédée von Moltke, an associate in the Brussels Office, contributed to the preparation of this Commentary.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Christian Fulda
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions